Kite Pharma Reports Favorable Data From Lymphoma Study
Zacks Investment Research | Sep 26, 2016 10:28PM ET
Kite Pharma, Inc. (NASDAQ:KITE) announced encouraging top-line data from a pre-planned interim analysis of a pivotal phase II portion of the ZUMA-1 study on its lead pipeline candidate, KTE-C19 (an anti-CD19 CAR-based therapy). The candidate is being evaluated for the treatment of patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). We expect investors to react positively to the news.
The ZUMA-1 study enrolled patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) into two cohorts. While cohort 1 enrolled patients with DLBCL, cohort 2 included patients with transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). Interim analysis of the first 51 patients showed that KTE-C19 achieved the primary endpoint of an objective response rate of 76%, including a complete remission rate of 47%. However, two patients died due to KTE-C19-related adverse events across the two cohorts of the study.
Kite Pharma plans to file for a regulatory approval for KTE-C19 in the DLBCL, TFL and PMBCL indications, based on combined data from both the cohorts. Meanwhile, the company intends to present additional data from the interim analysis at an upcoming scientific meeting. Moreover, the primary analysis of 101 patients with chemorefractory aggressive NHL (DLBCL, TFL and PMBCL), which will include about six months of follow-up data, is anticipated in the first quarter of 2017.
Kite Pharma is also evaluating KTE-C19 in three other pivotal studies. These include ZUMA-2 in patients with relapsed/refractory mantle cell lymphoma (MCL), ZUMA-3 in adults with acute lymphoblastic leukemia (ALL) and ZUMA-4 in pediatric ALL. The company expects to report data from ZUMA-2 and the phase II portions of ZUMA-3 and ZUMA-4 in 2017. Positive data from these studies would allow the company to file for an FDA approval for these indications.
KITE PHARMA INC Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.